IMU

5.41%

3.9¢ imugene limited

I said "However, my understanding is the last chemo treatment...

First 26 Last

Share
Profile

Follow
Fire Bull

1,251 Posts.

19

12/03/19

21:27

Post #: 37738507
Share

Originally posted by Fire Bull: ↑

No worries, it is good to question the comparison as the mistake could easily have been mine. The study protocols can be quite intricate so it is easily done.

Agree that the path of improvement is key. However, my understanding is the last chemo treatment was day 56 so perhaps improvement we are seeing at what I think is day 98 is still the effect of chemo. I don't know if these timelines are correct for sure or if this scenario is likely.

In the Herceptin + chemo v chemo alone trial, median OS was 13.8 v 11.1 but as Axel Hoos explains in the below video, even median OS is not necessarily a good measure for evaluating immunotherapy as there may be a significant minority of patients who experience longterm benefit.

Whilst the response data we have looks like what we might expect if the treatment is working as desired, it really doesn't tell us much hence the lack of share price reaction. Now, if we get news every 84 days of continuing improvement in the data as the final patient progresses then it becomes increasingly likely that HER-vaxx works. Even no improvement in response rates but continued survival would be significant over time.

Do we know how many patients actually died to date?

First patient dosing was at the end of August in 2017 so that is more than 18 months ago. Are they still alive? How many HER-vaxx boosters has each patient had to date? Some of them could have had a few of these by now.

My understanding (although I'm not certain) is that the data we have is for all patients as at day 56 and again at day 98. If this is correct then except for the last patient, Imugene would know the status of patients beyond these periods and in some cases significantly beyond. So what has become of them? Have they continued to improve?

Expand

I said "However, my understanding is the last chemo treatment was day 56 so perhaps improvement we are seeing at what I think is day 98 is still the effect of chemo."

On rereading the study design I think chemo could continue after day 56.

IMU Price at posting: 2.0¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CAF

IP anomaly thrills Cannidah with project extension hopes in QLD

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

C1X

iTech inks deal with Chilean lithium giant to progress Reynolds Range

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

ASX Market Open: Aussie market to leap on best 'Trump trade' bump since election day | November 22, 2024

CMB

Asian Battery Metals uncover second massive sulphide discovery at Mongolia's Oval play

PCL

HotCopper users react as Pancontinental Energy's trading halt lift reveals little

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ALY

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 18 more messages in this thread...

First 26 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.002(5.41%)		Mkt cap ! $386.7M

Open	High	Low	Value	Volume
3.6¢	4.0¢	3.5¢	$1.163M	31.27M

Buyers (Bids)

No.	Vol.	Price($)
6	2275218	3.8¢

Sellers (Offers)

Price($)	Vol.	No.
3.9¢	196677	3

View Market Depth

No.	Vol.	Price($)
18	5665336	0.018
14	3997559	0.017
6	2974375	0.016
10	3219799	0.015
4	497500	0.014

Price($)	Vol.	No.
0.019	400000	2
0.020	5410946	12
0.021	8494780	17
0.022	8757253	13
0.023	4826614	8

Last trade - 16.10pm 22/11/2024 (20 minute delay)

IMU (ASX) Chart

I said "However, my understanding is the last chemo treatment...

IP anomaly thrills Cannidah with project extension hopes in QLD

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

iTech inks deal with Chilean lithium giant to progress Reynolds Range

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

ASX Market Open: Aussie market to leap on best 'Trump trade' bump since election day | November 22, 2024

Asian Battery Metals uncover second massive sulphide discovery at Mongolia's Oval play

HotCopper users react as Pancontinental Energy's trading halt lift reveals little

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I said "However, my understanding is the last chemo treatment...

Top Stories

IP anomaly thrills Cannidah with project extension hopes in QLD

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

iTech inks deal with Chilean lithium giant to progress Reynolds Range

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

ASX Market Open: Aussie market to leap on best 'Trump trade' bump since election day | November 22, 2024

Asian Battery Metals uncover second massive sulphide discovery at Mongolia's Oval play

HotCopper users react as Pancontinental Energy's trading halt lift reveals little

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News